http://www.wellcome.ac.uk/News/Media-office/Press-releases/2014/WTP057419.htm
A £3.2 million grant from the Wellcome Trust will enable multiple partners around the world to quickly establish clinical trials at existing Ebola treatment centres. Partners include the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC), the University of Oxford, Médecins Sans Frontières (MSF), the World Health Organization (WHO), Institut Pasteur, Institut Pasteur de Dakar, Fondation Mérieux and the Global Health Network.
…
In August a WHO expert panel unanimously concluded that in such exceptional circumstances it would be ethical to evaluate unregistered investigational treatments in people with Ebola virus disease.Several potential interventions have shown promise in the laboratory, in animal studies on non-human primates, and in a small number of cases of compassionate intervention, but none has yet been tested for efficacy and safety in humans with Ebola. Any new drug needs to be evaluated within the rigorous settings of a clinical trial to assess whether it is doing more harm or good.
The belief system of the global medical system cannot entertain the simpler solutions. We can with high confidence state, that Intravenous Vitamin C, collodial/nano silver and natural antiviral oils would be safer as treatment protocols and would provide the validation of these solutions that these medical priests state they seek for corporate “unregistered investigational treatment”.
Further evidence of the collusion of academia and funding foundations in the fraud that are vaccines.
EbolaInfo 